



The Sarcoma Interest Group

Facts & Enrollment Information

About the Sarcoma Interest Group

The translational research program (TRP) of NRG Sarcoma Committee with the NCI Sarcoma Interest Group is aimed at enhancing the translational aspect of research in sarcoma for which the current priority is to identify new agents that sensitize sarcoma to radiotherapy for clinical trials development. As sarcomas are histologically diverse and may originate from any anatomical site, the TRP team consists of fundamental scientists and clinicians specialized in different sites and disciplines involved in the management of sarcoma patients to optimize its ability to convert basic research to clinical trials in this arena.

Goals

1. To serve as a platform and forum for the discussion of various pre-clinical translational ideas with a high likelihood of being developed into clinical trial concepts.
2. Evaluation and development of clinically important endpoints for phase I-II trials, such as compartmental disease control, biomarker response and novel imaging surrogates' signals of treatment response.
3. To facilitate the collaboration between individual institutions, industry partners, consortia, and co-operative groups in the development and design of clinical concepts.
4. To assist NCI disease-specific committees and other Interest Groups in evaluating concepts related to sarcoma.

Sarcoma Interest Group Chairperson

- Dian Wang, MD, (Rush University, dian_wang@rush.edu)

THE SARCOMA INTEREST GROUP

Facts & Enrollment Information

Teleconference Schedule

- The Sarcoma Interest Group meets virtually via the WebEx platform every fourth Wednesday of the month at 11:00 am.
- The group membership is approximately 50.

Activities and Accomplishments

Clinical Trials

1. MDM2 Inhibitor AMG-232 (KRT-232) and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (<https://clinicaltrials.gov/ct2/show/NCT03217266>) (ClinicalTrials.gov Identifier: NCT03217266).

Publications

2. P. Wong, P. Houghton, D.G. Kirsch, S.E. Finkelstein, A.M. Monjazebe, M. Xu-Welliver, A.P. Dicker, M. Ahmed, B. Vikram, B.A. Teicher, C.N. Coleman, M. Machtay, W.J. Curran, D. Wang, Combining targeted agents with modern radiotherapy in soft tissue sarcomas, J Natl Cancer Inst, 106 (2014).
3. A. Soni, F. Li, Y. Wang, M. Grabos, L.M. Krieger, S. Chaudhary, M.S.M. Hasan, M. Ahmed, C.N. Coleman, B.A. Teicher, R.L. Piekarz, D. Wang, G.E. Iliakis, Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks, Mol Cancer Ther, 17 (2018) 2206-2216.

Interested in becoming a member of the Sarcoma Interest Group?

- Please Contact the Interest Group Coordinator:

Masoor M. Ahmed, PhD

Radiation Research Program

National Cancer Institute

Division of Cancer Treatment & Diagnosis

THE SARCOMA INTEREST GROUP

Facts & Enrollment Information

Tel: 240-276-5700

Email: mansoor.ahmed@nih.gov